# ğŸ“… Daily Report - 2026-02-18

> ä»Šæ—¥ç­›é€‰å‡º **43** æ¡å†…å®¹ï¼Œæ¥è‡ª **2** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
*   **å•ç»†èƒä¸ç©ºé—´ç»„å­¦æ•´åˆåˆ†æ**ï¼šæ­ç¤ºå¤´é¢ˆç™Œå…ç–«æ£€æŸ¥ç‚¹é˜»æ»ååº”ä¸­ï¼Œä¿ƒé«“ç»†èƒä¸Tç»†èƒçš„ç»†èƒç±»å‹ç‰¹å¼‚æ€§ç›¸äº’ä½œç”¨ã€‚
*   **å¤šç»„å­¦æ­ç¤ºç»´ç”Ÿç´ Dè°ƒæ§å…ç–«-è‚ é“å¾®ç”Ÿæ€**ï¼šé˜æ˜ç»´ç”Ÿç´ Dåœ¨ç‚ç—‡æ€§è‚ ç—…ä¸­é€šè¿‡è°ƒèŠ‚å…ç–«-è‚ é“å¾®ç”Ÿæ€å’Œå…ç–«è€å—é€šè·¯å‘æŒ¥ä½œç”¨ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   **è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒä¸æ²»ç–—**ï¼šç ”ç©¶å¤´é¢ˆç™Œã€è‚ç™Œã€åµå·¢ç™Œã€é¼»å’½ç™Œç­‰å¤šç§ç™Œç—‡ä¸­ï¼Œå…ç–«ç»†èƒäº’ä½œã€ä¿¡å·é€šè·¯ï¼ˆå¦‚STATsã€NIKï¼‰åŠè¡¨è§‚é—ä¼ è°ƒæ§ï¼ˆå¦‚G9aã€HP1ï¼‰å¯¹è‚¿ç˜¤å‘ç”Ÿå‘å±•åŠæ²»ç–—ååº”çš„å½±å“ã€‚
*   **è‚ é“èŒç¾¤ä¸ä»£è°¢è°ƒæ§**ï¼šæ¢è®¨é«˜è„‚é¥®é£Ÿã€ç»´ç”Ÿç´ Dç­‰å› ç´ å¯¹è‚ é“èŒç¾¤ã€å®¿ä¸»å…ç–«ç¨³æ€åŠç‚ç—‡æ€§è‚ ç—…ã€è‰°éš¾æ¢­èŒæ„ŸæŸ“çš„å½±å“ã€‚
*   **ç¥ç»é€€è¡Œæ€§ç–¾ç—…ä¸ç²¾ç¥ç–¾ç—…**ï¼šåˆ†æé˜¿å°”èŒ¨æµ·é»˜ç—…ã€ç²¾ç¥åˆ†è£‚ç—‡ç­‰ç–¾ç—…ä¸­ï¼ŒåŸºå› è¡¨è¾¾ã€ç¥ç»å…ƒå¾®ç¯å¢ƒåŠä¿¡å·é€šè·¯çš„å˜åŒ–ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   **å¤šç»„å­¦æ•´åˆåˆ†æ**ï¼šç»“åˆå•ç»†èƒæµ‹åºï¼ˆscRNA-seqï¼‰ã€ç©ºé—´ç»„å­¦ã€16S rRNAæµ‹åºã€ChIP-Seqç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æå¤æ‚ç”Ÿç‰©ä½“ç³»ã€‚
*   **æ–°å‹ç”Ÿç‰©æ ‡å¿—ç‰©ä¸é¶ç‚¹å‘ç°**ï¼šé€šè¿‡é«˜é€šé‡æµ‹åºï¼Œå‘ç°STAT1/3åœ¨åµå·¢ç™Œä¸­çš„é¢„åä½œç”¨ï¼Œä»¥åŠG9aæŠ‘åˆ¶å‰‚åœ¨è‚ç™Œå…ç–«æ²»ç–—ä¸­çš„å¢æ•ˆæ½œåŠ›ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
æ–°å‹è¡€æ£€æŠ€æœ¯æœ‰æœ›å®ç°ç™Œç—‡æ—©æœŸç­›æŸ¥ï¼Œç ”ç©¶å‘ç°è„‘éƒ¨ç‚ç—‡ä¸å¼ºè¿«è¡Œä¸ºç›¸å…³ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- è‚ºç™Œæ—©æœŸå…ç–«é€ƒé€¸æœºåˆ¶ç ”ç©¶
- è„‘ç‚ç—‡ä¸å¼ºè¿«è¡Œä¸ºå…³è”æ€§æ¢ç´¢
- å•ç»†èƒRNAæµ‹åºæŠ€æœ¯ä¼˜åŒ–

**æŠ€æœ¯äº®ç‚¹**ï¼š
- åŸºäºDNAçº³ç±³æŠ€æœ¯å’ŒCRISPRçš„æ–°å‹å…‰åŸºè¡€æ£€ä¼ æ„Ÿå™¨
- é¶å‘å•ç»†èƒRNAæµ‹åºæŠ€æœ¯ä»¥æå‡è½¬å½•æœ¬æ£€æµ‹å’Œè¦†ç›–åº¦

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (39æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE301720 æ•´åˆçš„å•ç»†èƒå’Œç©ºé—´åˆ†ææ­ç¤ºäº†å¤´é¢ˆç™Œå…ç–«æ£€æŸ¥ç‚¹é˜»æ–­ååº”ä¸­ä¾èµ–äºä¸Šä¸‹æ–‡çš„é«“ç³»-Tç»†èƒç›¸äº’ä½œç”¨**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€immuneã€T cellã€single-cellã€spatial
- ğŸ“ **æè¿°**ï¼šContributors : Athena E Golfinos-Owens ; Taja Lozar ; Parth Khatri ; Rong Hu ; Paul M Harari ; Paul F Lambert ; Megan B Fitzpatrick ; Huy Q DinhSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground Approximately 15-20% of head and neck cancer squamous cell carcinoma (HNSCC) patients respond favorably to immune checkpoint blockade (ICB). Previous single-cell RNA-Seq (scRNA-Seq) studies identified immune features, including macrophage subset ratios and T-cell subtypes, in HNSCC ICB response. However, the spatial features of HNSCC-infiltrated immune cells in response to ICB treatment need to be better characterized.Methods Here, we perform a systematic evaluation of cell interactions between immune cell types within the tumor microenvironment using spatial omics data using complementary techniques from both 10X Visium spot-based spatial transcriptomics and Nanostring CosMx single-cell spatial omics with RNA gene panel including 435 ligands and receptors. In this study, we used integrated bioinformatics analyses to identify cellular neighborhoods of co-localizing cell types in single-cell spatial transcriptomics and proteomics data. In addition, we used both publicly available scRNA-Seq and in-house spatial RNA-Seq data to identify spatially constrained Ligand-Receptor interactions in Responder patients.Results With 522,399 single cells profiled with both RNA and protein from 26 patients, in addition to spot-resolved spatial RNA-Seq from 8 patients treated with ICB together with bioinformatics analysis of publicly available single-cell and bulk RNA-Seq, we have identified a spatial and cell-type specific context-dependency of myeloid and T cell interaction difference between Responders and Non-Responders. We defined further cellular neighborhood and the sources of chemokine CXCL9/10-CXCR3 interactions in Responders, emerging targets in ICB, as well as CXCL16-CXCR6, CCL4/5-CCR5, and other underappreciated and potential markers and targets for ICB response in HNSCC. In addition, we have contributed a rich data resource of cell-cell Ligand Receptor interactions for the immunotherapy and HNSCC research community.Discussion Our work provides a comprehensive single-cell and spatial atlas of immune cell interactions that correlate with response to ICB in HNSCC. We showcase how integrating multiple technologies and bioinformatics approaches can provide new insights into potential immune-based biomarkers of ICB response. Our ...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301720)

**2.** â­ **GSE319270 å¤šç»„å­¦æ­ç¤ºç»´ç”Ÿç´ Dåœ¨ç‚ç—‡æ€§è‚ ç—…ä¸­å¯¹å…ç–«-è‚ é“å¾®ç”Ÿç‰©ç¾¤ç›¸äº’ä½œç”¨å’Œè€å—æ€§é€šè·¯çš„å½±å“**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€gutã€regex:gut(-?microbiome)?
- ğŸ“ **æè¿°**ï¼šContributor : John GubatanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensLoss of immune tolerance to the gut microbiome plays a pathogenic role in inflammatory bowel disease (IBD). How dietary factors alter host immune-gut microbiome interactions in IBD is unclear. Here, we apply multi-omics (IgA-SEQ, IgG-SEQ, blood scRNA-seq and immune repertoire sequencing) to investigate the effects of 12 weeks of vitamin D on host immune microbe interactions in patients with IBD. Vitamin D treatment associates with decreased disease activity and inflammatory markers and increased IgA-bound and decreased IgG-bound gut microbiota. Vitamin D alters the profiles of IgA-bound (increased Lachnospiraceae, Blautia) and IgG-bound (decreased Proteobacteria, Enterococcaceae) gut bacteria. Vitamin D increases BAFF signaling between plasmacytoid dendritic cells and B cells, alters BCR and TCR clonotypes that associate with Ig-bound gut microbiota, and increases Î±4Î²7+ B and T regulatory cells. Our results demonstrate that vitamin D promotes immune tolerance to gut microbiota in patients with IBD. Clinical trial is registered under NCT04828031
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319270)

**3.** â­ **GSE319268 å¤šç»„å­¦æ­ç¤ºç»´ç”Ÿç´  D è°ƒèŠ‚ç‚ç—‡æ€§è‚ ç—…ä¸­çš„å…ç–«-è‚ é“å¾®ç”Ÿç‰©ç¾¤ç›¸äº’ä½œç”¨å’Œè€å—é€”å¾„ [16S rRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€gutã€regex:gut(-?microbiome)?
- ğŸ“ **æè¿°**ï¼šContributor : John GubatanSeries Type : OtherOrganism : human feces metagenomeLoss of immune tolerance to the gut microbiome plays a pathogenic role in inflammatory bowel disease (IBD). How dietary factors alter host immune-gut microbiome interactions in IBD is unclear. Here, we apply multi-omics (IgA-SEQ, IgG-SEQ, blood scRNA-seq and immune repertoire sequencing) to investigate the effects of 12 weeks of vitamin D on host immune microbe interactions in patients with IBD. Vitamin D treatment associates with decreased disease activity and inflammatory markers and increased IgA-bound and decreased IgG-bound gut microbiota. Vitamin D alters the profiles of IgA-bound (increased Lachnospiraceae, Blautia) and IgG-bound (decreased Proteobacteria, Enterococcaceae) gut bacteria. Vitamin D increases BAFF signaling between plasmacytoid dendritic cells and B cells, alters BCR and TCR clonotypes that associate with Ig-bound gut microbiota, and increases Î±4Î²7+ B and T regulatory cells. Our results demonstrate that vitamin D promotes immune tolerance to gut microbiota in patients with IBD. Clinical trial is registered under NCT04828031
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319268)

**4.** â­ **GSE319142 å¤šç»„å­¦æ­ç¤ºç»´ç”Ÿç´ Då¯¹ç‚ç—‡æ€§è‚ ç—…ä¸­å…ç–«-è‚ é“å¾®ç”Ÿç‰©ç¾¤ç›¸äº’ä½œç”¨å’Œè€å—é€”å¾„çš„è°ƒæ§**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€gutã€regex:gut(-?microbiome)?
- ğŸ“ **æè¿°**ï¼šContributor : John GubatanSeries Type : OtherOrganism : Homo sapiensLoss of immune tolerance to the gut microbiome plays a pathogenic role in inflammatory bowel disease (IBD). How dietary factors alter host immune-gut microbiome interactions in IBD is unclear. Here, we apply multi-omics (IgA-SEQ, IgG-SEQ, blood scRNA-seq and immune repertoire sequencing) to investigate the effects of 12 weeks of vitamin D on host immune microbe interactions in patients with IBD. Vitamin D treatment associates with decreased disease activity and inflammatory markers and increased IgA-bound and decreased IgG-bound gut microbiota. Vitamin D alters the profiles of IgA-bound (increased Lachnospiraceae, Blautia) and IgG-bound (decreased Proteobacteria, Enterococcaceae) gut bacteria. Vitamin D increases BAFF signaling between plasmacytoid dendritic cells and B cells, alters BCR and TCR clonotypes that associate with Ig-bound gut microbiota, and increases Î±4Î²7+ B and T regulatory cells. Our results demonstrate that vitamin D promotes immune tolerance to gut microbiota in patients with IBD. Clinical trial is registered under NCT04828031
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319142)

**5.** â­ **GSE319486 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ G9a æŠ‘åˆ¶å¯å¢å¼ºå…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚åœ¨å®éªŒæ€§è‚ç»†èƒç™Œä¸­çš„ç–—æ•ˆ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcarcinomaã€immuneã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Elena Adan-Villaescusa ; Borja Castello-Uribe ; Iker Uriarte ; Eva Santamaria ; Roberto Barbero ; Miriam Belzunce ; Amaya LÃ³pez-Pascual ; Maria Ujue Latasa ; Jasmin Elurbide ; Emiliana Valbuena-Goiricelaya ; Agavni Mesropian ; Guillem Cano-Segarra ; Ana HernÃ¡ndez de Sande ; Lorenzo Nevi ; Simone Carotti ; Umberto Vespasiani-Gentilucci ; Felipe Prosper ; Antonio Pineda-Lucena ; Bruno Sangro ; Josepmaria Argemi ; Pedro Berraondo ; Pablo Sarobe ; Albert Gris-Oliver ; Roser Pinyol ; Josep M Llovet ; Maria Arechederra ; Carmen Berasain ; Alexis Cocozaki ; Veronica Gibaja ; Matias A Avila ; Maite G Fernandez-BarrenaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusImmune checkpoint inhibitors (ICIs) have improved cancer therapy, but their efficacy in hepatocellular carcinoma (HCC) remains limited, partly associated with tumor-intrinsic mechanisms of immune evasion. To investigate potential epigenetic drivers of immune resistance, this study evaluated transcriptional changes following pharmacological inhibition of the histone methyltransferase G9a (EHMT2). Bulk RNA sequencing was performed on the murine NM53 and human PLC/PRF/5 HCC cell lines treated with G9a inhibitors. NM53 cells were treated with CM272 with or without interferon gamma (IFN-gamma), and PLC/PRF/5 cells were treated with EZM8266. Gene-level expression was quantified for both cell lines, and transposable element (TE) family-level expression was quantified for NM53 samples.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319486)

**6.** **GSE293444 STAT1 å’Œ STAT3 ä¿¡å·é€šè·¯åœ¨åµå·¢ç™Œä¸­çš„ä½œç”¨ï¼šé¢„åç”Ÿç‰©æ ‡å¿—ç‰©å’Œæ²»ç–—é¶ç‚¹ [RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Esther Rodman ; John HawseSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEpithelial ovarian cancer is the 7th most common cancer in women worldwide and is the most fatal of all female reproductive cancers. JAK/STAT signaling is oncogenic in ovarian cancer and has been reported to be constitutively active in a proportion of chemotherapy resistant ovarian cancer cell lines and tumors. However, the precise molecular mechanisms by which STAT1 and STAT3 function in ovarian cancer are not well understood and the consequences of their specific inhibition have yet to be determined. Methods: To delineate the specific functions of STAT1 and STAT3 in high grade serous and endometrioid ovarian cancer cell lines, we treated OVSAHO and MDAH cells with IFNÎ³ or IL6, canonical STAT1 and STAT3 activators respectively, with and without STAT1 or STAT3 specific siRNAs. We conducted RNA-sequencing and ChIP-sequencing following treatment to delineate direct and indirect target genes for STAT1 and STAT3. We generated a STAT1 and STAT3 specific gene signature and applied them to publicly available datasets to test their predictive and prognostic ability. Results: Using these global and unbiased datasets, we identified STAT1 and STAT3 specific pathways, developed STAT1 and STAT3 specific gene signatures, and applied these signatures to publicly available ovarian cancer patient data. We determined the STAT1 and STAT3 signatureâ€™s associations with tumor development, chemotherapy responsiveness and long-term patient outcomes. Conclusions: Our studies have further informed the precise mechanisms of STAT1 and STAT3 action in the two most common subtypes of ovarian cancer and have defined gene signatures that are both prognostic and predictive.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293444)

**7.** **GSE285714 NIK é©±åŠ¨çš„é«“ç³»ç»†èƒ IL-23 äº§ç”Ÿæ˜¯è‡ªèº«å…ç–«æ€§ç‚ç—‡å‘å±•çš„å…³é”®å› ç´  [scRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šinflammationã€scRNA
- ğŸ“ **æè¿°**ï¼šContributors : Nishada Ramphal ; Matthias Klein ; Ari WaismanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe have employed a single cell sequencing approach with BD Rhapsody to study the differences within myeloid cells in the draining lymph nodes four days after MOG immunisation between NIKfl/fl control mice and NIK^CX3CR1 mice
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285714)

**8.** **GSE313697 é«˜è„‚é¥®é£Ÿé‡å¡‘è‚ é“å®¿ä¸»-å¾®ç”Ÿç‰©ç¾¤å…³ç³»ï¼Œå¯¼è‡´è‰°éš¾æ¢­èŒæ„ŸæŸ“åé¢„åæ›´å·®**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šgutã€regex:gut(-?microbiome)?
- ğŸ“ **æè¿°**ï¼šContributors : Kumar Archit ; Nguyen Nhu T Q ; O'Brien Martin ; Young Vincent B ; Yung RaymondSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHigh-fat diet rewires gut host-microbiota relationship to derive worse outcomes following Clostridioides difficile infection
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313697)

**9.** **GSE302930 è†€èƒ±ç™Œè¡¨è§‚é—ä¼ å›¾è°±æ­ç¤ºç®¡è…”å‹å’ŒåŸºåº•é³çŠ¶åˆ†å­äºšå‹ä¸­çš„ä¸»è¦è½¬å½•å› å­å’Œé£é™©ç›¸å…³è°ƒæ§å…ƒä»¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€epigenetic
- ğŸ“ **æè¿°**ï¼šContributors : Elio Adib ; Amin H. Nassar ; Sarah Abou Alaiwi ; Toni K. Choueiri ; David J. Kwiatkowski ; Matthew L. FreedmanSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensWe performed histone ChIP-seq, the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq), and RNA sequencing (RNA-seq) on 28 fresh frozen bladder/upper tract tumor samples. We integrated 64 unique data sets to gain a holistic view of gene regulation in bladder cancer expression/molecular subtypes and nominated candidate subtype-specific master transcription factors (TF) driving expression differences. We also integrated bladder GWAS risk SNPs with H3K27ac ChIP-seq and ATAC-seq data and revealed that risk variants were significantly enriched in genetically determined peaks
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302930)

**10.** **GSE317145ï¼šç”¨GRK2æ´»æ€§è°ƒèŠ‚å‰‚æ²»ç–—Tg2576é˜¿å°”èŒ¨æµ·é»˜ç—…å°é¼ åçš„å…¨è½¬å½•ç»„å¾®é˜µåˆ—åŸºå› è¡¨è¾¾è°±åˆ†æ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šAlzheimerã€transcriptome
- ğŸ“ **æè¿°**ï¼šContributors : Joshua Abd Alla ; Ursula QuittererSeries Type : Expression profiling by arrayOrganism : Mus musculusWith increased aging of the global society, the prevalence of Alzheimer's Disease (AD) is on the rise worldwide. This study aimed to identify AD-related transcript changes in frontal cortex specimens of 18-month-old Tg2576 mice which were used as an experimental model of AD. This study analyzed frontal cortex specimens of two groups of 18-month-old Tg2576 AD mice. The first group was treated for 6 months with the GRK2 activity modulated, CPD10 [1-(1,3-Benzodioxol-5-yl)-4-(cyclopropanecarbonyl)-3-hydroxy-2-phenyl-2H-pyrrol-5-one] in drinking water (8 mg/kg/d) and the untreated control group of 18-month-old Tg2576 mice received tap water. The whole transcriptome microarray gene expression analysis identifies transcripts which were altered by treatment with the GRK2 activity modulator.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317145)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 29 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰

**1.** **é¶å‘å•ç»†èƒRNAæµ‹åºæŠ€æœ¯çš„å®ç”¨æŒ‡å—**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsequencingã€single-cell
- ğŸ“ **æè¿°**ï¼šThis review examines biases in RNA sequencing at the single cell level and outlines targeted strategies to improve transcript detection, coverage of internal regions, and experimental decision making...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/a-practical-guide-to-targeted-single-cell-rna-sequencing-technologies/)

**2.** **ç ”ç©¶äººå‘˜åœ¨è‚ºç™Œå‰ç—…å˜ä¸­å‘ç°äº†æ½œåœ¨çš„å…ç–«é€ƒé€¸æœºåˆ¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmune
- ğŸ“ **æè¿°**ï¼šUsing RNA sequencing, researchers identified miR-149-5p as a driver of immune evasion in progressive bronchial lesions, revealing a potential pathway for early lung cancer...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/researchers-identify-potential-immune-evasion-mechanism-in-premalignant-lung-lesions/)

**3.** **è„‘éƒ¨ç‚ç—‡å¯èƒ½æ˜¯å¯¼è‡´å¼ºè¿«è¡Œä¸ºçš„åŸå› ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šinflammation
- ğŸ“ **æè¿°**ï¼šFor years, compulsive behaviors have been viewed as bad habits stuck on autopilot. But new research in rats found the opposite: inflammation in a key decision-making brain region actually made behavior more deliberate, not more automatic. The change was linked to astrocytes, brain support cells that multiplied and disrupted nearby circuits. The discovery hints that some compulsive behaviors may arise from excessive, misdirected control rather than a loss of it.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/02/260215225606.htm)

**4.** **è¿™ç§æ–°çš„è¡€æ¶²æ£€æµ‹æ–¹æ³•å¯ä»¥åœ¨ç™Œç—‡æ‰«æç»“æœå‡ºæ¥ä¹‹å‰å°±æ£€æµ‹å‡ºç™Œç—‡ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancer
- ğŸ“ **æè¿°**ï¼šA new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, CRISPR, and quantum dots to generate a clear signal from just a few molecules. In lung cancer tests, it worked even in real patient serum samples. Researchers hope it could eventually power portable blood tests for cancer and other diseases.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/02/260216044002.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| single-cell | 8 |
| immune | 8 |
| RNA-seq | 7 |
| cancer | 6 |
| gut | 5 |
| regex:gut(-?microbiome)? | 5 |
| scRNA | 4 |
| transcriptome | 4 |
| sequencing | 2 |
| Alzheimer | 2 |
| inflammation | 2 |
| ChIP-seq | 2 |
| carcinoma | 2 |
| regex:immuno(logy|therapy|suppression) | 2 |
| Visium | 1 |
| histone | 1 |
| epigenetic | 1 |
| T cell | 1 |
| spatial | 1 |
| methylation | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (29æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE319431 äººé¼»å’½ç™Œç»†èƒåœ¨ BALF2â€‹â€‹-LR å’Œ BALF2â€‹â€‹-HR è¿‡è¡¨è¾¾ç»„ä¸­çš„ RNA-seq](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319431)
- [GSE289832 è„¾ç¥ç» NE-Î²2AR è½´é€šè¿‡è°ƒèŠ‚ä¸­æ€§ç²’ç»†èƒå…ç–«æŠ‘åˆ¶åŠ å‰§è„“æ¯’ç—‡æ€¥æ€§è‚¾æŸä¼¤ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289832)
- [GSE289831 è„¾ç¥ç» NE-Î²2AR è½´é€šè¿‡è°ƒèŠ‚ä¸­æ€§ç²’ç»†èƒå…ç–«æŠ‘åˆ¶åŠ å‰§è„“æ¯’ç—‡æ€¥æ€§è‚¾æŸä¼¤ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289831)
- [GSE285229 äº†è§£å«ä¹³è„‚é¥®é£Ÿå¯¹è‚ é“ä¸Šçš®ç¨³æ€çš„å½±å“ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285229)
- [GSE280985 å…ç–«èƒ†é“å•ç»†èƒå›¾è°±æ­ç¤ºäº†èƒ†ç®¡ç‚ä¸­ 2 å‹å¸¸è§„æ ‘çªçŠ¶ç»†èƒä¸ Î³Î´ T ç»†èƒä¹‹é—´çš„ç›¸äº’ä½œç”¨ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280985)
- [GSE280852 å…ç–«èƒ†é“å•ç»†èƒå›¾è°±è§£æèƒ†ç®¡ç‚ä¸­ 2 å‹å¸¸è§„æ ‘çªçŠ¶ç»†èƒä¸ Î³Î´ T ç»†èƒä¹‹é—´çš„ç›¸äº’ä½œç”¨ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280852)
- [GSE307866 é˜¿å°”èŒ¨æµ·é»˜ç—…é£é™©å› ç´ å’Œå±€éƒ¨ç¥ç»é»‘è‰²ç´ å«é‡å¯¹äººç±»è“æ–‘è½¬å½•ç»„å›¾è°±çš„å½±å“](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307866)
- [GSE307403 äººç±»å‰é¢å¶çš®å±‚çš®è´¨å±‚å’Œç»†èƒå¾®ç¯å¢ƒä¸­ä¸ç²¾ç¥åˆ†è£‚ç—‡ç›¸å…³çš„åŸºå› è¡¨è¾¾å˜åŒ– [Visium]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307403)
- [GSE300206 å¼‚æŸ“è‰²è´¨è›‹ç™½ 1 (HP1) çš„ç›¸åˆ†ç¦»æ§åˆ¶æ¶æ€§ç–ŸåŸè™«æ¯’åŠ›åŸºå› æ²‰é»˜ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300206)
- [GSE293317 STAT1 å’Œ STAT3 ä¿¡å·é€šè·¯åœ¨åµå·¢ç™Œä¸­çš„ä½œç”¨ï¼šé¢„åç”Ÿç‰©æ ‡å¿—ç‰©å’Œæ²»ç–—é¶ç‚¹](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293317)
- [GSE227793 å¯¹ä¸€ç»„æ‚£æœ‰å¿ƒæˆ¿é¢¤åŠ¨å’Œå¥åº·çª¦æ€§å¿ƒå¾‹çš„ä¸ªä½“çš„é…å¯¹å·¦å¿ƒæˆ¿å’Œå³å¿ƒæˆ¿è¿›è¡Œ H3K27ac å’Œ H3K4me3 ChIP-Seq åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE227793)
- [GSE304355 äººç±»ç‰¹å¼‚æ€§å¢å¼ºå­è°ƒèŠ‚æŸ“è‰²ä½“ç›¸äº’ä½œç”¨ä»¥ä¿ƒè¿›ç¥ç»å‘ç”Ÿ [å°é¼  RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304355)
- [GSE304354 äººç±»ç‰¹å¼‚æ€§å¢å¼ºå­è°ƒèŠ‚æŸ“è‰²ä½“ç›¸äº’ä½œç”¨ä»¥ä¿ƒè¿›ç¥ç»å‘ç”Ÿ [äººç±»å•ç»†èƒRNAæµ‹åº]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304354)
- [GSE318047 èƒ¶è´¨æ¯ç»†èƒç˜¤æ‚£è€…ï¼ˆç¬¬3ç»„ï¼‰äººè„‘çš®å±‚æ ‡æœ¬çš„å…¨è½¬å½•ç»„å¾®é˜µåˆ—åŸºå› è¡¨è¾¾è°±åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318047)
- [GSE318046 èƒ¶è´¨æ¯ç»†èƒç˜¤æ‚£è€…å¤§è„‘çš®å±‚æ ‡æœ¬çš„å…¨è½¬å½•ç»„å¾®é˜µåˆ—åŸºå› è¡¨è¾¾è°±åˆ†æï¼ˆç¬¬ 2 ç»„ï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318046)
- [GSE318045 èƒ¶è´¨æ¯ç»†èƒç˜¤æ‚£è€…å¤§è„‘çš®å±‚æ ‡æœ¬çš„å…¨è½¬å½•ç»„å¾®é˜µåˆ—åŸºå› è¡¨è¾¾è°±åˆ†æï¼ˆç¬¬1ç»„ï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318045)
- [GSE309790 å¼‚å¸¸DNAç”²åŸºåŒ–ä¸äº§å‰æš´éœ²å’Œæ–°ç”Ÿå„¿åŠå„¿ç«¥æœŸè‚¥èƒ–å¢åŠ æœ‰å…³](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309790)
- [GSE309460 æœ‰ä¸åˆ†è£‚åè½¬å½•æ¿€æ´»å’Œ 3D è°ƒæ§ç›¸äº’ä½œç”¨å¯¹é»è¿è›‹ç™½è€—ç«­è¡¨ç°å‡ºä½ç‚¹å’Œåˆ†åŒ–ç‰¹å¼‚æ€§æ•æ„Ÿæ€§ [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309460)
- [GSE288300 æœ‰ä¸åˆ†è£‚åè½¬å½•æ¿€æ´»å’Œ 3D è°ƒæ§ç›¸äº’ä½œç”¨å¯¹é»è¿è›‹ç™½è€—ç«­è¡¨ç°å‡ºä½ç‚¹å’Œåˆ†åŒ–ç‰¹å¼‚æ€§æ•æ„Ÿæ€§ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288300)
- [GSE208730 RNAæµ‹åºï¼šå°é¼ èƒŒéƒ¨çš®è‚¤ã€å°¾éƒ¨çš®è‚¤å’Œå£è…”ä¸Šçš®ä¸­æ…¢é€Ÿå’Œå¿«é€Ÿå¾ªç¯è¡¨çš®å¹²ç»†èƒä¸æ¯›å›Šå¹²ç»†èƒçš„æ¯”è¾ƒ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208730)
- [GSE319500 åµå·¢ç™Œæ— è¿›å±•ç”Ÿå­˜æœŸçš„å¯é¢„æµ‹æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319500)
- [GSE319460 ç³–å°¿ç—…å’Œè„“æ¯’ç—‡å°é¼ è‚ é“è½¬å½•ç»„åˆ†æ [miRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319460)
- [GSE311681 å…ç–«èƒ†é“å•ç»†èƒå›¾è°±è§£æèƒ†ç®¡ç‚ä¸­2å‹å¸¸è§„æ ‘çªçŠ¶ç»†èƒä¸Î³Î´ Tç»†èƒä¹‹é—´çš„ç›¸äº’ä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311681)
- [GSE297569 ä¿å®ˆçš„éç¼–ç åºåˆ— CNS11 æ˜¯ 17 å‹å…ç–«ç»†èƒä¸­ Rorc è½¬å½•çš„ä¸»æ§åŒº [4C-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297569)
- [GSE297567 ä¿å®ˆéç¼–ç åºåˆ— CNS11 æ˜¯ 17 å‹å…ç–«ç»†èƒä¸­ Rorc è½¬å½•çš„ä¸»æ§åŒº [CUT&Tag]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297567)
- [GSE281197 å…ç–«èƒ†é“å•ç»†èƒå›¾è°±è§£æèƒ†ç®¡ç‚ä¸­ 2 å‹å¸¸è§„æ ‘çªçŠ¶ç»†èƒä¸ Î³Î´ T ç»†èƒä¹‹é—´çš„ç›¸äº’ä½œç”¨ [multiplex_and_CITE_seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281197)
- [GSE281196 å…ç–«èƒ†é“å•ç»†èƒå›¾è°±æ­ç¤ºäº†èƒ†ç®¡ç‚ä¸­ 2 å‹å¸¸è§„æ ‘çªçŠ¶ç»†èƒä¸ Î³Î´ T ç»†èƒä¹‹é—´çš„ç›¸äº’ä½œç”¨ [Multiome]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281196)
- [GSE277350ï¼šå¸•é‡‘æ£®ç—…æ‚£è€…æ¥æºçš„iPSCsä¸­å°‘çªèƒ¶è´¨ç»†èƒè°±ç³»ç»†èƒçš„å•ç»†èƒè½¬å½•ç»„å˜åŒ–ï¼ˆLRRK2-G2019Sçªå˜ï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277350)
- [GSE174547 è¡€ç®¡çº¿ç²’ä½“å…´å¥‹æ•ˆåº”å°† Mfn2 ä¸æ”¹å–„çš„ç³»ç»Ÿä»£è°¢å’Œå¥åº·å¯¿å‘½è”ç³»èµ·æ¥](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174547)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-17 21:51*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*